Rheumatoid Arthritis (RA) Clinical Trial
Official title:
Post-marketing Surveillance to Evaluate the Safety and Effectiveness of Upadacitinib in Korean Patients
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints characterized by the swelling of multiple joints and tenderness caused by progressive inflammatory synovitis, which leads to serious and debilitating diseases. Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Ankylosing Spondylitis (AS) is a form of chronic arthritis causing inflammation in the spine. This can cause pain and stiffness in the back. Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by the body's immune system mistakenly attacking healthy joint tissue causing inflammation, joint damage, disability, and a reduced life expectancy. This study will assess the adverse events and change in disease symptoms in Korean participants with RA, AD, AS or PsA. Upadacitinib is a drug approved for the treatment of moderately to severely active rheumatoid arthritis, atopic dermatitis, ankylosing spondylitis or psoriatic arthritis. Korean participants who have been prescribed upadacitinib by their physicians will be enrolled. Approximately, 3600 participants will be enrolled this study, in multiple sites within Korea. Participants will receive Upadacitinib as prescribed by the physician and will be followed for approximately 28 weeks. There will be no additional burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic and will be asked to provide additional information by questionnaire at each visit.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05047341 -
A Study of Human Substance Balance and Biotransformation of [14C]SHR0302
|
Phase 1 | |
| Withdrawn |
NCT02786563 -
Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate
|
||
| Completed |
NCT03257852 -
A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate
|
Phase 2 | |
| Completed |
NCT03660059 -
A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)
|
Phase 3 | |
| Recruiting |
NCT03971253 -
Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
|
||
| Not yet recruiting |
NCT05486715 -
Vitamin d Level and it's Association With Disease Activity in Egyptian Rheumatoid Arthritis Patients
|
||
| Completed |
NCT03682705 -
A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis
|
Phase 2 | |
| Active, not recruiting |
NCT04574492 -
A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis
|
||
| Active, not recruiting |
NCT02805010 -
Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously
|
Phase 1 | |
| Completed |
NCT01871961 -
Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient
|
Phase 1 | |
| Completed |
NCT04497597 -
A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis
|
||
| Terminated |
NCT02775656 -
UCB Cimzia Pregnancy Follow-up Study
|
||
| Completed |
NCT01173120 -
Methotrexate - Inadequate Response Device Sub-Study
|
Phase 3 | |
| Completed |
NCT03223012 -
Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
|
||
| Completed |
NCT03086343 -
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
|
Phase 3 | |
| Terminated |
NCT01569152 -
Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)
|
Phase 2 | |
| Completed |
NCT02105129 -
A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523
|
Phase 1 | |
| Completed |
NCT01618955 -
Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device
|
Phase 2 | |
| Completed |
NCT01577563 -
Prevalence Study of Gastrointestinal Risk Factors in Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS).
|
N/A | |
| Completed |
NCT01618968 -
Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device
|
Phase 2 |